Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies

Mohsenzadegan, M. and Seif, F. and Farajollahi, M.M. and Khoshmirsafa, M. (2018) Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. Recent Patents on Anti-Cancer Drug Discovery, 13 (2). pp. 224-239.

Full text not available from this repository.
Official URL:


Background: Tumor cells may be expressed as a result of oxidative stress. The extent of oxidative stress correlates with the aggressive and metastatic potency of cancer. Objective: One simple way to control prostate cancer is through chemoprevention which refers to the administration of natural or synthetic agents to block, reverse, or delay the process of carcinogenesis. The most chemopreventive agents are antioxidants in nature. Methods: In this review, we summarized the effects of dietary antioxidants with a focus on their molecular mechanisms and possible roles in the treatment of prostate cancer cells. We also reported the recent outcomes of laboratory and/or clinical trials of antioxidants in prostate cancer patients. Results: Numerous pre-clinical studies showed that antioxidants protect DNA against being damaged by Reactive Oxygen Species (ROS), thereby genetic mutations causing cancer are likely to be prevented. However, the clinical trial results showed that antioxidants have yielded mixed outcomes or benefitted only a subgroup of the population. Conclusion: A greater understanding of the molecular events associated with antioxidants will enhance the development of treatment and could result in better strategies for the chemoprevention of prostate cancer. Recent patents also suggest that anti-oxidant compounds can be effective for the prevention and the treatment of prostate cancer. © 2018 Bentham Science Publishers.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: active hexose correlated compound; alpha tocopherol; antioxidant; ascorbic acid; curcumin; daidzein; fungal extract; genistein; glutathione peroxidase; glycitein; immunoglobulin enhancer binding protein; isoflavone; lycopene; mitogen activated protein kinase 1; mitogen activated protein kinase 3; multivitamin; pomegranate extract; prostate specific antigen; quercetin; reactive oxygen metabolite; reduced nicotinamide adenine dinucleotide phosphate oxidase; resveratrol; retinol; selenium; silibinin; sinecatechins; thymoquinone; unclassified drug; unindexed drug, antineoplastic activity; antioxidant activity; apoptosis; cancer chemotherapy; cancer risk; castration resistant prostate cancer; cell cycle regulation; cell proliferation; chemoprophylaxis; diet supplementation; dietary intake; DNA damage; down regulation; edible mushroom; gene expression; gene mutation; human; hyperthermia; metastasis; nonhuman; oxidative stress; phase 2 clinical trial (topic); priority journal; prostate cancer; prostatectomy; protein expression; quality of life; randomized controlled trial (topic); Review; soybean meal; tea
Subjects: WJ Urogenital System
Depositing User: eprints admin
Date Deposited: 04 Dec 2018 12:15
Last Modified: 04 Dec 2018 12:15

Actions (login required)

View Item View Item